Knockdown of LncRNA PVT1 inhibits glioma progression by regulating miR-424 expression.
This study investigated the function and mechanism of PVT1 knockdown in the proliferation and malignant transformation of human gliomas. We firstly examined the expression levels of PVT1 and miR-424 in human glioma tissues and cell lines. We also used gene manipulation techniques to explore the effects of PVT1 knockdown on cell viability, migration, invasion, and miR-424. We found that PVT1 knockdown effectively inhibited cell viability, migration and invasion of human glioma cells and increased miR-424 expression. Based on the negative correlation between PVT1 and miR-424, we then confirmed the direct interaction between PVT1 and miR-424 using RNA immunoprecipitation (RIP) and luciferase reporter assays. Further, we established a xenograft nude mouse model to determine the role and mechanism of PVT1 on tumor growth in vivo. In addition, PVT1 knockdown was shown to promote miR-424 in vivo. In summary, the present study demonstrated that PVT1 knockdown could negatively regulate miR-424 to inhibit human glioma cell activity, migration and invasiveness. PVT1 knockdown could negatively regulate miR-424 to inhibit cellular activity, migration and invasiveness in human gliomas, which explained the oncogenic mechanism of PVT1 in human gliomas. It also suggested that PVT1 might be a novel therapeutic target for human gliomas. PMID: 30832754 [PubMed - as supplied by publisher]
AbstractBackgroundUntil now, there is no clear conclusion on the relationship between the surgical margin status after radical prostatectomy (RP) and prostate cancer-specific mortality (PCSM). Therefore, we conducted this systematic review and meta-analysis based on all eligible case –control studies.MethodsA systematic and comprehensive literature search was performed based on PUBMED and EMBASE to identify all of the potentially relevant publications which were published before September 2019. Hazard ratio (HR) for PCSM was independently extracted by two reviewers from all eligible studies. Pooled HR estimates with ...
ConclusionThe findings declare that inhibition ofPVT1 could be a new target in the treatment of AML-M0 and help to approach more to treatments with fewer side effects.
AbstractPurposeTo identify patients with metastatic urothelial cancer (mUC) unlikely to benefit from immune-checkpoint inhibitors (ICIs).Methods/PatientsWe explored the predictive and prognostic values of baseline neutrophil-to-lymphocyte ratio (NLR), with cut-offs ≥ 3 and ≥ 5, and of a urothelial immune prognostic index (UIPI, based on increased NLR and LDH), on 146 patients.ResultsNLR and UIPI significantly predicted progressive disease and progression-free survival with both cut-offs (p = 0.0069,p = 0.0034,p = 0.0160,p = 0.0063;p
ConclusionsIn conclusion, both the venous access catheter selection algorithm and the proposed recommendations aim to respond to the needs revealed in clinical practice and to become an integrable tool in electronic prescription systems to offer homogeneous criteria for action in cancer patients that require venous access, optimizing the use of available health resources with the highest safety and quality of life for the patient.
ConclusionmiR-1976 may serve as a promising non-invasive biomarker for the diagnosis of BC in the future.
AbstractIn this update of the consensus of the Spanish Society of Medical Oncology (Sociedad Espa ñola de Oncología Médica—SEOM) and the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica—SEAP), advances in the analysis of biomarkers in advanced colorectal cancer (CRC) as well as susceptibility markers of hereditary CRC and molecular biomarkers of localized CRC are reviewed. Recently published information on the essential determination ofKRAS,NRAS andBRAF mutations and the convenience of determining the amplification of human epidermal growth factor ...
Expect another 30 to 40 years of increasing numbers of HPV-related oropharynx cancers, said an expert.Medscape Medical News
Authors: MacDonald-Ramos K, Michán L, Martínez-Ibarra A, Cerbón M Abstract Silymarin is obtained from the Milk thistle plant Silybum marianum and has been used over the centuries to treat principally liver disease, although it has also been studied for its beneficial effects in cardioprotection, neuroprotection, immune modulation, and cancer among others. Importantly, silymarin's active component silybin is a flavonolignan that exhibits different activities such as; scavenger, anti-oxidant, anti-inflammatory, and recently revealed, insulin-sensitizing properties which have been explored in clin...
Patients with HR+, HER2- breast cancer at high risk of early recurrence on endothelial therapy could highly improve their invasive disease-free survival with adjuvant abemaciclib, a new trial shows.Medscape Medical News